136 related articles for article (PubMed ID: 6235888)
1. Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
Kerle D; Williams G; Ware H; Bloom SR
Br Med J (Clin Res Ed); 1984 Aug; 289(6443):468-9. PubMed ID: 6235888
[No Abstract] [Full Text] [Related]
2. Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
Ahmed SR; Shalet SM; Grant J; Howell A; Blacklock NJ
Br Med J (Clin Res Ed); 1984 Sep; 289(6448):831. PubMed ID: 6236870
[No Abstract] [Full Text] [Related]
3. Prostatic cancer: treatment with long-acting LHRH analogue.
Williams G; Allen JM; O'Shea JP; Mashiter K; Doble A; Bloom SR
Br J Urol; 1983 Dec; 55(6):743-6. PubMed ID: 6228283
[TBL] [Abstract][Full Text] [Related]
4. Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.
Labrie F; Dupont A; Belanger A; Lachance R; Giguere M
Br Med J (Clin Res Ed); 1985 Aug; 291(6492):369-70. PubMed ID: 3926197
[TBL] [Abstract][Full Text] [Related]
5. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.
Allen JM; O'Shea JP; Mashiter K; Williams G; Bloom SR
Br Med J (Clin Res Ed); 1983 May; 286(6378):1607-9. PubMed ID: 6221774
[TBL] [Abstract][Full Text] [Related]
6. Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system.
Williams G; Kerle D; Griffin S; Dunlop H; Bloom SR
Br Med J (Clin Res Ed); 1984 Dec; 289(6458):1580-1. PubMed ID: 6239674
[No Abstract] [Full Text] [Related]
7. LHRH.
Glode LM; Smith JA
JAMA; 1985 Jul; 254(4):506-7. PubMed ID: 3892064
[No Abstract] [Full Text] [Related]
8. Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
Kreis W; Ahmann FR; Jordan VC; de Haan H; Scott M
Br J Urol; 1988 Oct; 62(4):352-4. PubMed ID: 2973364
[TBL] [Abstract][Full Text] [Related]
9. In regard to Padula et al., normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. IJROBP 2002;52: 439-443.
Dearnaley DP; Norman AR; Shahidi M
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):981; author reply 981. PubMed ID: 12377353
[No Abstract] [Full Text] [Related]
10. Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma.
Walker KJ; Nicholson RI; Turkes AO; Turkes A; Griffiths K; Robinson M; Crispin Z; Dris S
Lancet; 1983 Aug; 2(8347):413-5. PubMed ID: 6135908
[TBL] [Abstract][Full Text] [Related]
11. [Treatment with D-Trp-6-LHRH. Plasma levels and gonadotropic response].
Lahlou N; Duchier J; Feinstein MC; Mauvernay RY; Roger M; Schally AV
Pathol Biol (Paris); 1984 Oct; 32(8):906-8. PubMed ID: 6209605
[No Abstract] [Full Text] [Related]
12. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
[No Abstract] [Full Text] [Related]
13. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
Waxman JH; Wass JA; Hendry WF; Whitfield HN; Besser GM; Malpas JS; Oliver RT
Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1309-12. PubMed ID: 6404441
[TBL] [Abstract][Full Text] [Related]
14. Endocrine and clinical effects of leuprolide in prostatic cancer.
Vance MA; Smith JA
Clin Pharmacol Ther; 1984 Sep; 36(3):350-4. PubMed ID: 6432399
[TBL] [Abstract][Full Text] [Related]
15. Re: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
Guess B; Scholz M
J Urol; 2001 May; 165(5):1644-5. PubMed ID: 11345950
[No Abstract] [Full Text] [Related]
16. Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer.
Allen JM; Kerle DJ; Ware H; Doble A; Williams G; Bloom SR
Br Med J (Clin Res Ed); 1983 Dec; 287(6407):1766. PubMed ID: 6315133
[No Abstract] [Full Text] [Related]
17. Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?
Borgmann V; Hardt W; Schmidt-Gollwitzer M; Adenauer H; Nagel R
Lancet; 1982 May; 1(8281):1097-9. PubMed ID: 6122893
[TBL] [Abstract][Full Text] [Related]
18. Sustained impairment of pituitary and testicular function in prostatic cancer patients treated with a depot form of a GnRH agonist.
Rolandi E; Franceschini R; Giberti C; Brancadoro T; Martorana G; Barreca T
Horm Res; 1988; 30(1):22-5. PubMed ID: 2975631
[TBL] [Abstract][Full Text] [Related]
19. Failure to maintain the suppressed level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
Kinouchi T; Maeda O; Ono Y; Meguro N; Kuroda M; Usami M
Int J Urol; 2002 Jun; 9(6):359-61. PubMed ID: 12110102
[TBL] [Abstract][Full Text] [Related]
20. Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer.
Spitz IM; Chertin B; Lindenberg T; Farkas A
N Engl J Med; 1999 May; 340(18):1439. PubMed ID: 10328706
[No Abstract] [Full Text] [Related]
[Next] [New Search]
